Details of the Drug Combination

General Information of Drug Combination (ID: DCASBPE)

Drug Combination Name
Prasugrel Vorapaxar
Indication
Disease Entry Status REF
Myocardial Infarction Phase 4 [1]
Component Drugs Prasugrel   DM7MT6E Vorapaxar   DMA16BR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Prasugrel
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Prasugrel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
P2Y purinoceptor 12 (P2RY12) TTZ1DT0 P2Y12_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Prasugrel Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [6]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Vorapaxar
Disease Entry ICD 11 Status REF
Myocardial infarction BA41-BA43 Approved [3]
Stroke 8B20 Investigative [4]
Vorapaxar Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proteinase activated receptor 1 (F2R) TTL935N PAR1_HUMAN Antagonist [7]
------------------------------------------------------------------------------------
Vorapaxar Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Myocardial Infarction DC97619 N. A. Phase 4 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02545933) Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7562).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4047).
4 Vorapaxar FDA Label
5 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6 The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
7 In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8.
8 Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.